APM Aptorum Group Limited: Market Capitalization to Book Value Ratio

Official company branding of aptorumgroup.com (APM)

The current price chart for Aptorum Group Limited (APM) on the GURU.Markets platform demonstrates the asset's dynamics, with a value of 0.24. Aptorum Group Limited generates revenue by implementing advanced medtech in the US and Hong Kong, as well as through the licensing of treatments for rare pathologies. Capitalization is supported by unique patents in the field of infection control, while operational efficiency is maintained through the outsourcing of trials and a lean workforce.

Aptorum Group (APM) - Market Capitalization to Book Value Ratio from 07/04/2022 to 07/20/2026
Finished products of Aptorum Group Limited

Aptorum Group Limited is optimizing preclinical costs through an audit of external research contractors. This strategy impacts the net asset value, which is divided by market capitalization to determine the valuation ratio. This metric captures the gap between the real value of resources and market expectations. High values signal speculative overvaluation, creating downside risks. By analyzing this chart of the multiple by which market cap exceeds book value, an investor determines the extent of the premium paid for the business.

Direct competitors

Market Value to Book Value Ratio Haleon plc (HLN)|kenvue.com (KVUE) - Market Capitalization to Net Assets|VRNA - Market Capitalization to Book Value Ratio|Market Value to Book Value Jyong Biotech Limited|Market Capitalization to Book Value Ratio LGND|Market Capitalization to Book Value Ratio AMRX (Amneal Corp)|Market Value to Book Value Ratio Perrigo Company plc|alvotech.com - Market Value to Book Value|LQDA: Market Value to Book Value Ratio|GLPG - Market Cap to Net Assets Ratio|ANIP: Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Afrezza|AMPH - Market Cap to Net Assets Ratio|Market Value to Book Value PCRX|ARS Pharmaceuticals, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio Theravance Biopharma Inc TBPH|Market Cap to Net Assets Ratio Aquestive Pharma (AQST)|Market Cap to Book Value Multiple scPharmaceuticals, Inc. SCPH|Market Capitalization to Book Value Ratio Tectonic (TECX)|TNXP - Market Value to Book Value|Market Capitalization to Book Value Ratio SXTC|EPRX (Eupraxia Pharmaceuticals Inc.) - Market-to-Book Ratio|BHST - Market Value to Book Value Ratio|Market Value to Book Value Invizyne|Market Capitalization to Book Value Ratio ORMP|Market Capitalization to Book Value Ratio ENTX (enterabio.com)|MindWalk Holdings Inc. (HYFT) - Market Value to Book Value Ratio|ABVC - Market Capitalization to Net Assets|Market Cap to Net Assets Ratio Cumberland Pharma CPIX|QNTM: Market Cap to Book Value Multiple|Market Value to Book Value Ratio FGEN|TELO (telomirpharma.com) - Market-to-Book Ratio|RANI - Market Value to Book Value Ratio|Market Value to Book Value Synergy CHC Corporation (SNYR)|Market Cap to Net Assets Ratio RLYB|Market Capitalization to Book Value Ratio LEXX (lexariabioscience.com)|Pulmatrix, Inc. - Market Value to Book Value Ratio|PTHL - Market Cap to Net Assets Ratio|Market Cap to Net Assets Ratio Lyra Therapeutics (LYRA)|IBO - Market Value to Book Value|Market Capitalization to Book Value Ratio TNFA (tnfpharma.com)|YCBD (cbdMD) - Market Value to Equity Ratio|PRFX - Market Value to Book Value Ratio|Market Value to Book Value CYTO|Lipella Pharmaceuticals, Inc. - Market Value to Book Value Ratio|Market-to-Book Ratio OptiNose Inc OPTN|Market Cap to Net Assets Ratio PIRS (Pieris)|Procaps Group Corp - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Petros Pharmaceuticals|qlsyy.net (QLI) - Market Capitalization to Net Assets|Market Cap to Net Assets Ratio ACELYRIN SLRN|TFFP (TFF Pharmaceuticals Inc.) - Market Value to Book Value